Publication
Title
Clinical achievements of the EORTC Lymphoma Group and aspects of future group strategy
Author
Institution/Organisation
EORTC Lymphoma Grp
Abstract
Since1964, the EORTC Lymphoma Group has conducted nine consecutive randomized phase III trials on early-stage Hodgkin lymphoma aimed at increasing efficacy while decreasing short- and long-term toxicities. Event-free and overall survival significantly improved from about 50% and 70%, respectively, in the early years to over 80% and 90%, respectively, more recently. Identification of prognostic subgroups appeared to be a successful method to tailor treatment strategies. Radiotherapy fields have become more restricted whereas chemotherapy has become standard. Early PET-CT has been introduced to investigate the possibility of treatment adaptation. Longitudinal quality-of-life assessment has become an integral part of our studies. An ongoing study focuses on the rehabilitation and quality of long-term survival in all 6658 Hodgkin lymphoma patients treated in EORTC trials since the earliest beginning. In advanced stages overall outcome has improved as well with 10-year survival rates of over 75%. (C) 2012 European Organisation for Research and Treatment of Cancer. All rights reserved.
Language
English
Source (journal)
European journal of cancer : supplements. - Amsterdam, 1990, currens
Publication
Amsterdam : 2012
ISSN
1359-6349 [print]
1878-1217 [online]
Volume/pages
10:1(2012), p. 105-111
ISI
000302130800017
Full text (Publisher's DOI)
Full text (open access)
UAntwerpen
Faculty/Department
Research group
[E?say:metaLocaldata.cgzprojectinf]
Publication type
Subject
Affiliation
Publications with a UAntwerp address
External links
Record
Identification
Creation 14.05.2012
Last edited 09.10.2014
To cite this reference